Clincosm LogoSign in Get a demo

GPAS: Glioblastoma Platelet Activation Study

Sponsor
University Medicine Greifswald (Other)
Overall Status
Completed
CT.gov ID
NCT02887417
Collaborator
(none)
21
Enrollment
1
Location
11
Duration (Months)
1.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

    Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    21 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Study Start Date :
    Jan 1, 2016
    Actual Primary Completion Date :
    Oct 1, 2016
    Actual Study Completion Date :
    Dec 1, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    patients

    glioblastoma patients
    controls

    healthy controls

    Outcome Measures

    Primary Outcome Measures

    1. Mean P-selectine expression in all platelets [01/ 2016 - 10/ 2016]

    2. Mean CD63 expression in all platelets [01/ 2016 - 10/ 2016]

    3. Mean CD40 Expression in all platelets [01/ 2016 - 10/ 2016]

    4. Mean platelet-monocyte-conjugate formation in the monocyte population [01/ 2016 - 10/ 2016]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • MR-morphological suspicion for glioblastoma

    • informed consent

    Exclusion Criteria:
    • no informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Neurosurgery Greifswald Germany 17475

    Sponsors and Collaborators

    • University Medicine Greifswald

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sascha Marx, Dr. med., University Medicine Greifswald
    ClinicalTrials.gov Identifier:
    NCT02887417
    Other Study ID Numbers:
    • Glioma-HGW
    First Posted:
    Sep 2, 2016
    Last Update Posted:
    Aug 1, 2017
    Last Verified:
    Jul 1, 2017
    Keywords provided by Sascha Marx, Dr. med., University Medicine Greifswald
    platelet activation
    Additional relevant MeSH terms:
    Glioblastoma

    Study Results

    No Results Posted as of Aug 1, 2017